MedTrace Logo

Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer

NCT04903782 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2022-11-04

No results posted yet for this study

Summary

Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients

Conditions

  • Neoplastic Syndromes, Hereditary
  • Cancer
  • Genetic Predisposition to Disease

Interventions

DIAGNOSTIC_TEST

Family-based whole genome sequencing

1. Germline whole-genome family-based sequencing and variant identification. 2. Multidisciplinary Meeting case discussion. 3. Recommendation of referral to a Cancer Genetics Clinic for further investigation, follow up and/or genetic counselling. 4. Psychosocial study to analyse the impact of germline sequencing on families.

Sponsors & Collaborators

  • Children's Cancer Institute Australia

    collaborator UNKNOWN

  • Sydney Children's Hospitals Network

    lead OTHER

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2023-03-08
Completion
2028-06-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04903782 on ClinicalTrials.gov